U.S. Building Stock News

Metropolitan Bank Holding (MCB) has completed and filed follow-on equity offerings totaling roughly US$353.5 million, issuing 2,100,000 common shares at US$85, a move that directly affects existing and prospective shareholders. See our latest analysis for Metropolitan Bank Holding. The follow on offerings come after a strong 1 year total shareholder return of 41.92% and a 3 year total shareholder return of 56.43%. However, recent momentum has cooled, with a 7 day share price return showing an...

If you are wondering whether Natera's current share price reflects its real value, you are not alone. This article will help you frame that question clearly. Natera's share price last closed at US$216.10, with a 7 day return of 0.1% decline, a 30 day return of 10.1% decline, a year to date return of 5.6% decline, and a 1 year return of 38.0%, alongside a very large 3 year return and a 111.6% return over 5 years. Recent headlines around Natera have kept the stock on many investors'...

Magnite (MGNI) closed out FY 2025 with Q4 revenue of US$205.4 million and basic EPS of US$0.86, capped by trailing 12 month EPS of US$1.01 that sits on trailing 12 month revenue of US$714.0 million. Over the past six quarters in this dataset, revenue has moved from US$162.0 million in Q3 2024 to US$205.4 million in Q4 2025, while quarterly EPS shifted from US$0.04 to US$0.86, creating a backdrop where margins have become a central focus for investors assessing the latest print. See our full...

In February 2026, Watsco, Inc. reported that its fourth-quarter 2025 sales fell to US$1,578.76 million and net income to US$71.75 million, and also approved a 10% increase in its annual dividend to US$13.20 per share for both Common and Class B shares. The combination of softer recent earnings and a higher dividend, underpinned by management’s emphasis on improved gross margins and a debt-free balance sheet, highlights how Watsco is prioritizing shareholder returns while contending with...

If you are looking at Credicorp and wondering whether the current share price still reflects solid value, you are not alone. This article will walk through what the numbers actually say. The stock last closed at US$355.48, with returns of 1.7% over 7 days, a marginal 0.2% decline over 30 days, 24.1% year to date, 106.7% over 1 year and 183.7% over 5 years. This naturally raises questions about how much future upside or risk is already built in. Recent news coverage has focused on Credicorp's...

Paylocity Holding (PCTY) is in focus after second quarter results came in ahead of guidance, prompting higher revenue projections for fiscal 2026 and an updated outlook for total and recurring revenues. See our latest analysis for Paylocity Holding. The second quarter beat and upgraded fiscal 2026 revenue outlook arrive after a mixed share price run, with an 8.52% 1 day share price return and 6.59% 7 day share price return contrasting with a 19.95% 30 day share price decline and a 44.87% 1...

Rhythm Pharmaceuticals (RYTM) has wrapped up FY 2025 with Q4 revenue of US$57.3 million and a basic EPS loss of US$0.73, while trailing 12 month figures show total revenue of US$189.8 million and a basic EPS loss of US$3.11. Over recent quarters, the company has seen revenue move from US$41.8 million in Q4 2024 to US$57.3 million in Q4 2025, with basic EPS losses ranging between US$0.72 and US$0.82 per quarter. This sets up a story where revenue is building but margins remain under...

In February 2026, Jackson Financial Inc. reported fourth-quarter 2025 revenue of US$1,988 million but swung to a net loss of US$204 million, while also increasing its common dividend, declaring a preferred dividend, and completing a large share repurchase program that retired just over 40% of its shares since 2021. Despite record retail annuity sales and continued capital returns, the sharp drop in yearly net income to US$27 million and a move from earnings per share to a loss per share have...

Ultragenyx Pharmaceutical (NasdaqGS:RARE) announced that the US FDA has accepted its Biologics License Application for DTX401, a gene therapy for Glycogen Storage Disease Type Ia. The FDA has granted Priority Review to the application, signaling an expedited assessment timeline. If approved, DTX401 could become the first pharmacologic treatment option for people living with Glycogen Storage Disease Type Ia. For Ultragenyx, with a current share price of $23.04, this regulatory milestone...

If you are looking at OceanFirst Financial and wondering whether its current share price lines up with its underlying worth, you are asking the exact question this article is built to tackle. The stock last closed at US$19.04, with returns of 3.8% over the past 30 days, 6.7% year to date, and 12.8% over the past year. The 3 year and 5 year returns sit at a 5.6% decline and a 5.0% gain respectively. These share price moves sit against a backdrop of ongoing sector wide attention on US regional...

MarketAxess Holdings (NasdaqGS:MKTX) has appointed William Quan as Chief Technology Officer to lead its AI and technology modernization efforts. The company has also announced an integration with DirectBooks that is designed to streamline primary market workflows for its clients. MarketAxess runs an electronic trading platform focused on fixed income markets, connecting institutional investors and dealers in credit products. The arrival of William Quan as CTO brings a leader with experience...

Several class action lawsuits have been filed against NuScale Power (NYSE:SMR) alleging misrepresentations about key commercialization partner ENTRA1 Energy. Plaintiffs claim NuScale understated the risks tied to ENTRA1, as fresh details emerge about substantial payments and project delays. At the same time, NuScale received approval for a small modular reactor project in Romania and major shareholder Fluor announced plans to exit its position. NuScale Power, trading at $13.33, is facing a...

Pennant Group’s FY 2025 Earnings Set Up the Next Phase of the Story The Pennant Group (PNTG) closed FY 2025 with fourth quarter revenue of US$289.3 million and basic EPS of US$0.25, capping a trailing twelve month period where revenue reached US$947.7 million and EPS came in at US$0.86. Over the past six reported quarters, the company has seen revenue move from US$188.9 million in Q4 2024 to US$289.3 million in Q4 2025, while quarterly EPS ranged between US$0.17 and US$0.25. This leaves...

If you are looking at Benchmark Electronics and wondering whether the current share price reflects its true worth, this article will walk through the key pieces you need to weigh that question up. The stock most recently closed at US$59.18, with returns of 3.2% over 7 days, 20.8% over 30 days, 34.8% year to date, 52.0% over 1 year and 163.2% over 3 years, so valuation now sits front and center for many investors. Recent coverage has focused on Benchmark Electronics as an established...

Pebblebrook Hotel Trust (PEB) has wrapped up FY 2025 with Q4 revenue of US$349.0 million, a basic EPS loss of US$0.23, and trailing twelve month revenue of about US$1.5 billion alongside a full year basic EPS loss of US$0.90. This gives investors a clear view of where the top line stands in relation to still negative earnings. The company has reported quarterly revenue moving from US$404.5 million in Q3 2024 to US$349.0 million in Q4 2025, while quarterly basic EPS has ranged from a loss of...

If you are wondering whether Atlanta Braves Holdings is fairly priced or trading at a premium, you are in the right place to unpack what the current share price might be telling you about value. The stock last closed at US$43.98, with reported returns of 2.5% over 7 days, 10.9% over 30 days, 10.3% year to date, 11.4% over 1 year and 50.1% over 5 years. These figures often prompt investors to reassess both upside potential and risk. Recent coverage around Atlanta Braves Holdings has focused...

Sezzle (SEZL) just wrapped up FY 2025 with Q4 revenue of US$129.9 million and basic EPS of US$1.26, rounding out a trailing twelve months that delivered US$450.3 million in revenue and EPS of US$3.93. Over the past few quarters, the company has seen revenue move from US$69.96 million in Q3 2024 to US$98.22 million in Q4 2024, then to US$104.9 million in Q1 2025 and US$129.9 million in Q4 2025. Quarterly EPS shifted from US$0.46 in Q3 2024 to US$0.75 in Q4 2024 and climbed through 2025 to...

Celsius Holdings (CELH) closed out FY 2025 with Q4 revenue of US$721.6 million and basic EPS of US$0.04, alongside trailing twelve month revenue of about US$2.5 billion and EPS of US$0.25. This provides a clear snapshot of where the business stands after a volatile year. The company reported quarterly revenue of US$332.2 million in Q4 2024 and US$721.6 million in Q4 2025, while EPS moved from a loss of US$0.09 to a profit of US$0.04 over the same period. This sets up a results season in which...

IDEXX Laboratories (NasdaqGS:IDXX) announced the upcoming retirement of long-serving Board member M. Anne Szostak. The company also disclosed the appointment of Michael G. Erickson, PhD, to its Board of Directors. These Board changes reflect an ongoing refresh of corporate governance and Board composition. IDEXX Laboratories focuses on diagnostic and software solutions for veterinary practices, livestock, poultry, and water testing, placing the company at the center of long term trends in...

If you are wondering whether Bilibili’s current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers actually say about value. Bilibili’s stock has been volatile, with a 7 day return of an 8% decline, a 30 day return of a 17.9% decline, but a 1 year return of 37.5% and a 3 year return of 32.0%. This gives mixed signals about how the market is currently pricing the business. Recent headlines around Bilibili have focused on its...

DXP Enterprises (DXPE) has wrapped up FY 2025 with Q4 revenue of US$527.4 million and basic EPS of US$1.46, alongside net income excluding extraordinary items of US$22.8 million. On a trailing twelve month basis, revenue stands at about US$2.0 billion with EPS of US$5.65 and net income of US$88.6 million. The company has seen quarterly revenue move from US$470.9 million in Q4 2024 to US$527.4 million in Q4 2025, with basic EPS shifting from US$1.36 to US$1.46 over the same period. This puts...

Luckin Coffee (OTCPK:LKNC.Y) has wrapped up FY 2025 with fourth quarter revenue of about C¥12.8b and basic EPS of C¥1.62, rounding out a year in which trailing twelve month revenue reached roughly C¥49.3b and EPS came in at about C¥11.23. The company has seen quarterly revenue move from roughly C¥9.6b in Q4 2024 to C¥12.8b in Q4 2025, while basic EPS shifted from C¥2.64 to C¥1.62 over the same period, setting up a mixed picture that investors will likely weigh against the reported net income...

In February 2026, Aspen Aerogels reported fourth-quarter 2025 sales of US$41.34 million versus US$123.09 million a year earlier, swung to a net loss of US$72.91 million, recorded an impairment charge on property, plant and equipment, and launched a broad review of options for its business and capital structure. An important insight is that management characterizes this strategic review as coming from a position of financial strength and operational progress, even as the company posts a...

LandBridge (LB) just wrapped up FY 2025 with fourth quarter revenue of US$56.8 million and basic EPS of US$0.29, while trailing twelve month EPS came in at US$1.08 on revenue of US$199.1 million, setting a clear reference point for how the business is currently earning its profits. The company has seen revenue move from US$36.5 million in Q4 2024 to US$56.8 million in Q4 2025, with quarterly EPS shifting from US$0.12 to US$0.29 over the same stretch. Those figures sit alongside trailing...